
Sharon Fekrat, MD, FACS, FASRS, of Duke University, discusses how retinal imaging fits into the diagnostic picture for CVI, TBI, and neurodegenerative disease, and when eye care professionals should suspect a neurological cause.
The latest in drug and technology developments and updates from July 2025.
Major news on the presbyopia forefront closed out July with the FDA's approval of Lenz Therapeutics’ VIZZ (aceclidine 1.44%). The first and only FDA-approved aceclidine eye drop for presbyopia was met with other formative developments in multiple specialties in eye care, including retina, dry eye, and lid and lash. Learn the latest in our roundup of what to take away from the month of July in terms of drug and technology updates below:






